CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

givosiran

Last Updated: February 23, 2021
Result type: Reports
Project Number: SR0679-000
Product Line: Reimbursement Review

Generic Name: givosiran

Brand Name: Givlaari

Manufacturer: Alnylam Netherlands B.V.

Therapeutic Area: Acute hepatic porphyria (AHP) in adults

Indications: ​Treatment of acute hepatic porphyria (AHP) in adults

Manufacturer Requested Reimbursement Criteria1: Treatment of acute hepatic porphyria (AHP) in adults

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJanuary 25, 2021
Call for patient/clinician input closedMarch 19, 2021
Submission receivedFebruary 23, 2021
Submission accepted-
Submit Feedback